Biotech’s Iron Lady: The Story of Dr. Zanganeh

Together, Zanganeh and Duggan turned their attention to cancer treatment, joining a new company, Pharmacyclics, in 2003. Duggan had a personal stake in this mission—his son had died of brain cancer. The duo focused on developing novel therapies, eventually leading to a groundbreaking deal in 2011 with Johnson & Johnson that included a $400 million upfront payment and allowed Pharmacyclics to retain U.S. marketing rights.